Pernod Ricard to Integrate Malibu-Kahlúa International Brands into the Absolut Company on July 1st, 2009
6.4.2009 13:58:21 CEST | Business Wire | Press release
Pernod Ricard to Integrate Malibu-Kahlúa International Brands into the Absolut Company on July 1 st , 2009
Regulatory News:
Following the successful acquisition of Allied Domecq in 2005 and since its creation in 2006, Malibu-Kahlúa International (MKI), a subsidiary of Pernod Ricard (Paris:RI), has created strong marketing foundations for Malibu, and its two liqueur brands Kahlúa and Tia Maria.
Malibu is the number one coconut-flavoured rums in the world, sold in more than 150 countries. Kahlúa and Tia Maria are the Group two coffee liqueurs, Kahlúa being the world’s leader in its category.
Recognizing the need to significantly increase the level of support behind these dynamic brands and to maximise efficiency, Pernod Ricard has decided to leverage the resources of The Absolut Company (TAC), the Swedish subsidiary in charge of the leading brand of Premium Vodka, Absolut, which offers many synergies.
As a result, the Malibu-Kahlúa International brands will be consolidated within The Absolut Company and will be managed out of Stockholm, Sweden effective with the new fiscal year 2009/10, July 1st , 2009.
About Pernod Ricard
Created by the merger of Pernod and Ricard (1975), the Group has
undergone sustained development, based on both organic growth and
acquisitions.
The purchase of part of Seagram (2001), the
acquisitions of Allied Domecq (2005) and recently of Vin & Sprit (2008)
have made Pernod Ricard the world’s co-leader in wines and spirits with
sales of € 6,589 million in 2007/08.
Pernod Ricard holds one
of the most prestigious brand portfolios in the sector: ABSOLUT Premium
Vodka, Ricard pastis, Ballantine’s, Chivas Regal and The Glenlivet
Scotch whiskies, Jameson Irish Whiskey, Martell cognac, Havana Club rum,
Beefeater gin, Kahlúa and Malibu liqueurs, Mumm and Perrier-Jouët
champagnes, as well Jacob’s Creek and Montana wines.
The
Group favours a decentralised organisation, with 7 Brand Owners and 70
Distribution Companies established in each key market, and employs a
workforce of more than 19,300 people.
Pernod Ricard is
strongly committed to a sustainable development policy and encourages
responsible consumption.
Pernod Ricard is listed on the NYSE
Euronext exchange (Ticker: RI; ISIN code: FR0000120693) and is a member
of the CAC 40 index.
Shareholders’ agenda: 2008/09 3rd Quarter sales– Thursday 30 April 2009
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
Pernod Ricard
Francisco de la VEGA / Communication VP
Tel:
+33 (0)1 41 00 40 96
or
Florence TARON / Press Relations
Manager
Tel: +33 (0)1 41 00 40 88
or
Denis FIEVET /
Financial Communication - Investor Relations VP
Tel: +33 (0)1 41 00
41 71
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom